Rahul Mishra, DO
Pain Medicine · Frisco, TXNPI 1487881124
Payments from drug & device makers
Across 509 payments — averaging $43.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$11K
- Medtronic$3K
- Nevro Corp.$1K
- Redhill Biopharma Inc.$916
- Collegium Pharmaceutical, Inc.$798
- Forte Bio-pharma LLC$716
- plus $4K from 29 others
What the payments were for
- Consulting fees$8304%
- Speaking & faculty fees$10,52048%
- Travel & lodging$1,4337%
- Food & beverage$9,16942%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 28 | $10,832 |
| Medtronic(2 entities) | 81 | $3,136 |
| Nevro Corp. | 31 | $1,127 |
| Redhill Biopharma Inc. | 8 | $916 |
| Collegium Pharmaceutical, Inc. | 63 | $798 |
| Forte Bio-pharma LLC | 34 | $716 |
| Scilex Pharmaceuticals Inc. | 29 | $506 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 27 | $444 |
| Pfizer | 31 | $412 |
| AbbVie(2 entities) | 19 | $347 |
| Zyla Life Sciences, Inc. | 24 | $293 |
| Epimed International, Inc | 2 | $259 |
| Daiichi Sankyo Inc. | 30 | $259 |
| Abbott | 10 | $244 |
| Arbor Pharmaceuticals, Inc. | 13 | $220 |
| IBSA Pharma Inc. | 10 | $163 |
| Boston Scientific | 9 | $149 |
| Azurity Pharmaceuticals, Inc. | 9 | $146 |
| Kowa Pharmaceuticals America, Inc. | 8 | $128 |
| Gilead | 1 | $117 |
| Vertex | 4 | $108 |
| Biotronik NRO, Inc. | 5 | $88 |
| Almatica Pharma LLC | 5 | $78 |
| Biodelivery Sciences International, Inc. | 5 | $70 |
| Pacira Therapeutics, Inc. | 5 | $66 |
| Baudax Bio Inc. | 1 | $50 |
| Assertio Therapeutics, Inc. | 3 | $48 |
| Johnson & Johnson | 3 | $47 |
| Lundbeck LLC | 2 | $41 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Virtus Pharmaceuticals LLC | 2 | $27 |
| Valinor Pharma, LLC | 1 | $20 |
| Si-bone, Inc. | 1 | $15 |
| Pernix Therapeutics Holdings, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RAYOS$15,720
- PENNSAID$4,480
- VenaSeal$902
- OSTEOCOOL RF ABLATION$871
- MOVANTIK$830
- KRYSTEXXA$800
- Nalocet$493
- Prolate$386
- Catheters and Needles$152
- Senza Spinal Cord Stimulation System$140
- Epidural Needles and Catheters$107
How this compares
$21,952 in reported general payments places this provider in the 85th percentile of 583 pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 920 | $27,364 |
| MovantikNaloxegol Oxalate | 48 | $19,606 |
| Xtampza ErOxycodone Myristate | 16 | $15,259 |
| OxycontinOxycodone Hcl | 29 | $14,119 |
| ZtlidoLidocaine | 14 | $11,965 |
| Lidocaine | 40 | $7,687 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 222 | $6,255 |
| Fentanyl | 49 | $5,280 |
| Oxycodone Hcl | 296 | $4,906 |
| Gabapentin | 289 | $3,484 |
| Pregabalin | 174 | $2,739 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 15 | $2,680 |
| Cyclobenzaprine Hcl | 169 | $2,072 |
| Morphine Sulfate | 71 | $1,974 |
| Tramadol Hcl | 165 | $1,436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Redhill Biopharma Inc.Movantik | $916 | $19,60648 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $798 | $15,25916 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $506 | $11,96514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 583 pain medicine providers in Texas.
Other pain medicine in Frisco
- David KeelenFrisco$35K
- Shamim BadiyanFrisco$24K
- Aaron CalodneyTyler$3M
- Mitchell EngleHouston$1.5M
- Melissa MurphyGrapevine$711K
- Shiraz YazdaniLubbock$632K
- Muhammad ZulqarnainDallas$556K
- Daniel PakHouston$460K
- Marvin ChangSugar Land$306K
- David LeimanHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.